Get the Stockscreener App
1.58
4.24%
-0.07
Outlook Therapeutics Inc stock is traded at $1.58, with a volume of 20.44M.
It is down -4.24% in the last 24 hours and up +589.35% over the past month.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$1.65
Open:
$1.62
24h Volume:
20.44M
Relative Volume:
1.21
Market Cap:
$234.77M
Revenue:
$424.90K
Net Income/Loss:
$-94.02M
P/E Ratio:
-0.636
EPS:
-2.4842
Net Cash Flow:
$-51.25M
1W Performance:
+43.64%
1M Performance:
+589.35%
6M Performance:
-23.67%
1Y Performance:
-5.95%
1-Day Range:
$1.40
$1.66
1-Week Range:
$1.12
$1.70
52-Week Range:
$0.1611
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.58 | 234.77M | 424.90K | -94.02M | -51.25M | -2.4842 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-25 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-02-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-13-23 | Initiated | CapitalOne | Overweight |
| Apr-03-23 | Initiated | Guggenheim | Buy |
| Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-22 | Initiated | BTIG Research | Buy |
| Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| May-16-19 | Initiated | Oppenheimer | Outperform |
| Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
Outlook Therapeutics StockWeekly review and sector context for biotech eye drug maker - AD HOC NEWS
OTLK stock up 35% as FDA accepts resubmitted eye drug BLA for review - MSN
Outlook Therapeutics Inc (OTLK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
One Month, One Drug, One Verdict: Outlook Therapeutics' Lytenava Awaits FDA's Answer on July 29 - AD HOC NEWS
OTLK stock soars 28% after FDA sets July date for Lytenava decision - MSN
Outlook Therapeutics Heads Into Another FDA PDUFA Decision For Lytenava (NASDAQ:OTLK) - Seeking Alpha
Outlook Therapeutics Secures FDA Class-1 Review for Lytenava, Yet Cash Crunch and European Slowdown - AD HOC NEWS
Outlook Therapeutics’ Lytenava Nears FDA Verdict as Shares Skyrocket — But RSI Flashes Caution - AD HOC NEWS
OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision - Stocktwits
Outlook Therapeutics Inc (OTLK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Outlook Therapeutics Inc (OTLK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
FDA accepts Outlook Therapeutics' resubmitted BLA for ONS-5010 (LYTENAVA) - Ophthalmology Times
OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review - The Globe and Mail
Outlook Therapeutics Eye Drug Review Returns To FDA — AgainOutlook Therapeutics (NASDAQ:OTLK) - Benzinga
FDA accepts resubmitted BLA from Outlook Therapeutics - The Pharma Letter
Outlook Therapeutics (OTLK) Gains FDA Acknowledgment for BLA Res - GuruFocus
Outlook Therapeutics (OTLK) Stock After FDA Review Win Is The Valuation Case Already Priced In - Yahoo Finance
Outlook Therapeutics Stock Jumps as FDA Accepts Lytenava BLA, July Decision Looms - TechStock²
Outlook Therapeutics (OTLK) Gains After FDA Reconsiders ONS-5010 Application - GuruFocus
Outlook Therapeutics Shares Surge After FDA Accepts Resubmitted Wet AMD Application - marketscreener.com
Outlook Therapeutics stock surges on FDA BLA resubmission - Investing.com
Why Is OTLK Stock Falling Today? - Stocktwits
Outlook Therapeutics stock surges on FDA BLA resubmission By Investing.com - Investing.com UK
Outlook wet AMD therapy regains FDA review (OTLK:NASDAQ) - Seeking Alpha
Outlook Therapeutics: FDA accepts resubmitted BLA for ONS-5010 with PDUFA date July 29, 2026 - TradingView
FDA sets July 29, 2026 PDUFA date for Outlook Therapeutics (OTLK) ONS-5010 BLA - Stock Titan
Outlook Therapeutics Announces FDA Acceptance of Resubmitted BLA for ONS-5010 - marketscreener.com
FDA accepts Outlook Therapeutics’ resubmitted drug application - Investing.com
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD - The Manila Times
Wet AMD eye drug LYTENAVA enters FDA review before July 29 action date - Stock Titan
Outlook Therapeutics (OTLK) Is Up 60.7% After FDA Class 1 Review Acceptance For Lytenava - simplywall.st
Outlook Therapeutics Surges As FDA Fast-Tracks ONS-5010 Review - timothysykes.com
Why Outlook Therapeutics (OTLK) Is Up 57.1% After FDA Validates LYTENAVA Efficacy and BLA Resubmission - Yahoo Finance
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits
OTLK Jumps As Outlook Therapeutics Wins FDA Backing On BLA Resubmission - timothysykes.com
OTLK Stock Jumps As FDA Fast-Tracks Lytenava Review - timothysykes.com
OTLK Stock Jumps As FDA Fast-Tracks Lytenava Resubmission - StocksToTrade
OTLK Stock Jumps As FDA Fast-Tracks Lytenava Decision - timothysykes.com
Outlook Therapeutics (OTLK) Stock After FDA Class 1 BLA Resubmission Is The Valuation Out Of Line - simplywall.st
📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈 - Moomoo
OTLK Maintained by Ascendiant Capital -- Price Target Raised to $10.00 - GuruFocus
Outlook Therapeutics Gains as FDA Timeline for Lytenava Comes Up - TechStock²
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
OTLK stock surges over 50% pre-market, breaches key technical milestone – what’s behind this massive rally? - MSN
Outlook Therapeutics gains on FDA appeal win, boosting chances for Lytenava approval. - Pluang
Outlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunity (NASDAQ:OTLK) - Seeking Alpha
Outlook Therapeutics director Haddadin Yezan Munther buys $24,145 in shares - Investing.com UK
Outlook Therapeutics director Haddadin Yezan Munther buys $24,145 in shares By Investing.com - Investing.com South Africa
Outlook Therapeutics (OTLK) Stock Forum and Discussion - Moomoo
Director at Outlook Therapeutics (NASDAQ: OTLK) buys 29,000 shares - Stock Titan
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):